MARKET

IBIO

IBIO

Ibio
AMEX

Real-time Quotes | Nasdaq Last Sale

0.2800
+0.0470
+20.17%
Pre Market: 0.2799 -0.0001 -0.04% 07:11 05/23 EDT
OPEN
0.2400
PREV CLOSE
0.2330
HIGH
0.2896
LOW
0.2370
VOLUME
100
TURNOVER
--
52 WEEK HIGH
1.755
52 WEEK LOW
0.2230
MARKET CAP
61.09M
P/E (TTM)
-1.8337
1D
5D
1M
3M
1Y
5Y
66 Biggest Movers From Friday
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.
Benzinga · 3h ago
iBio to Participate in the H.C. Wainwright Global Investment Conference
BRYAN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming® Manufacturing System, today announced that it will...
GlobeNewswire · 4d ago
iBio quarterly net loss widens 61% even as revenue shows strong gain
IBio's (NYSE:IBIO) Q1 2022 net loss widened 61% to $12.4M (-$0.06 per share) despite a ~155% year-over-year revenue increase. Revenue of ~$1.9M in the quarter compared to $765K in the
Seekingalpha · 05/13 16:55
iBio: Q3 Earnings Insights
iBio (AMEX:IBIO) reported its Q3 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings iBio missed estimated earnings by 20.0%, reporting an EPS of $-0.06 versus an estimate of $-0.05.
Benzinga · 05/12 22:37
iBio GAAP EPS of -$0.06 in-line, revenue of $1.94M beats by $1.74M
iBio press release (NYSE:IBIO): Q3 GAAP EPS of -$0.06 in-line. Revenue of $1.94M (+155.3% Y/Y) beats by $1.74M. CEO comment: “We anticipate there may be a notable medical and business
Seekingalpha · 05/12 20:07
-- Earnings Flash (IBIO) IBIO Reports Q3 Revenue $1.9M
MT Newswires · 05/12 16:23
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/12 12:42
iBio FQ3 2022 Earnings Preview
iBio (NYSE:IBIO) is scheduled to announce FQ3 earnings results on Thursday, May 12th, after market close. The consensus EPS Estimate is -$0.06 (-50.0% Y/Y) and the consensus Revenue Estimate is
Seekingalpha · 05/11 21:35
More
No Data
Learn about the latest financial forecast of IBIO. Analyze the recent business situations of Ibio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IBIO stock price target is 1.750 with a high estimate of 2.500 and a low estimate of 1.000.
High2.500
Average1.750
Low1.000
Current 0.2800
EPS
Actual
Estimate
-0.06-0.04-0.03-0.01
    0
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 16
Institutional Holdings: 332.24K
% Owned: 0.15%
Shares Outstanding: 218.17M
TypeInstitutionsShares
Increased
4
14.06K
New
2
19.83K
Decreased
3
6.98K
Sold Out
1
250
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.90%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Chairman/President/Chief Executive Officer/Director
Thomas Isett
Chief Financial Officer/Chief Accounting Officer
Robert Lutz
Chief Scientific Officer
Martin Brenner
Independent Director
Linda Armstrong
Independent Director
Glenn Chang
Independent Director
William Clark
Independent Director
James Hill
Independent Director
Alexandra Kropotova
Independent Director
John McKey
Independent Director
Evert Schimmelpennink
Independent Director
Gary Sender
No Data
No Data
About IBIO
iBio, Inc. is a developer of biopharmaceuticals and FastPharming Manufacturing System. The Company is applying its technologies to develop product candidates to treat or prevent fibrotic diseases, cancers, and infectious diseases. The Company is using its FastPharming Manufacturing System (FastPharming System) and Glycaneering Services to build a portfolio of biologic drug candidates. The Company is also using the FastPharming System to create proteins for others by contract through the Company’s catalog. The Company operates through two segments: Biopharmaceuticals and Bioprocessing. Its Biopharmaceuticals segment, which includes development and licensing in two business units: therapeutics and vaccines. Its Bioprocessing, which includes services and products for research and further manufacturing uses, collectively known as Research & Bioprocess products (RBP). Its pipeline includes IBIO-100, IBIO-101, IBIO-202 and IBIO-400.

Webull offers kinds of Ibio Inc stock information, including AMEX:IBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IBIO stock methods without spending real money on the virtual paper trading platform.